- Melanotan II is a non-selective melanocortin receptor agonist sold illicitly as a tanning agent; it is not an approved drug and is associated with documented safety concerns.
- No female-specific pigmentation or safety analysis of Melanotan II exists in the indexed literature, and its early human studies focused largely on men, so its effects in women remain unstudied.
- Its more selective metabolite, bremelanotide (PT-141), was developed separately and is the melanocortin compound that carries an FDA-approved female indication, which is where women's melanocortin evidence actually lives.
Few research compounds have a gap this wide between how much people talk about them and how little controlled evidence supports them. Melanotan II is a synthetic melanocortin receptor agonist that circulates informally as a tanning agent, yet it is not an approved drug and is associated with documented safety concerns. For a database written around female physiology, the honest headline is that the women's evidence here is essentially empty, and saying so is the whole point.
Chemically, Melanotan II is a cyclic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). Its ring structure improves stability relative to the native hormone, and its non-selective activity across melanocortin receptors makes it a broad tool compound for studying the melanocortin system as a whole rather than any single receptor.
What the mechanism actually is
Melanotan II is a non-selective agonist across melanocortin receptors. Activation at MC1R drives melanogenesis, the pigmentation signaling that gives the compound its tanning reputation, while activation at MC4R produces central effects that the literature has associated with appetite and sexual function. That breadth is exactly why it engages so many pathways at once, and also why its effects are hard to isolate cleanly.
The female evidence, stated plainly
There is no controlled female pigmentation or safety analysis for Melanotan II in the indexed literature. The early human studies of the compound skewed heavily toward men, including erectile-function work, so there is no sex-specific characterization to report. Every women's-angle field here reads as unstudied, not because the questions are unimportant but because the studies were never done in women.
- Sex differences: unstudied; early human work focused largely on men, with no female-specific pigmentation or safety analysis.
- Menstrual cycle: no studies examine cycle interactions.
- Hormonal interactions: no data on estrogen, thyroid, or contraceptive interactions.
- Perimenopause and menopause: no data in perimenopausal or menopausal populations.
There is no approved dose for Melanotan II. Early studies used subcutaneous dosing, which is noted here only for context, not as a protocol, instruction, or medical advice. This site does not publish personal dosing.
Where the female melanocortin evidence does exist
If you are looking for melanocortin research that actually includes women, the compound to look at is not this one. Melanotan II's more selective relative, bremelanotide (PT-141), was developed separately and is FDA-approved for a female indication. That is the melanocortin molecule whose record contains real female data. Melanotan II, by contrast, is the broad, unregulated tool version of the same receptor family.
Melanotan II has no safety data and is an unregulated compound. It is not presented as safe in pregnancy, breastfeeding, or while trying to conceive, and the absence of any safety characterization is itself the reason to avoid it in those states.
The most useful thing a female-focused catalog can do with Melanotan II is refuse to invent evidence for it. The mechanism is real and interesting; the women's data is not there. You can see the full unstudied breakdown on the Melanotan II profile, where the blank states are tracked as first-class facts rather than filled in.